camidanlumab tesirine + pembrolizumab

**Camidanlumab tesirine + pembrolizumab** is an investigational combination therapy comprised of an antibody-drug conjugate (camidanlumab tesirine, also known as ADCT-301 or Cami) targeting CD25 (the alpha subunit of the interleukin-2 receptor) and a checkpoint inhibitor (pembrolizumab, a programmed death 1 (PD-1) receptor inhibitor). Camidanlumab tesirine consists of a human IgG1 anti-CD25 monoclonal antibody conjugated via a cleavable linker to a pyrrolobenzodiazepine (PBD) dimer cytotoxic payload. Following binding to CD25 on cell surfaces (including Tregs and CD25+ tumor cells), the conjugate is internalized and the payload released, inducing DNA interstrand cross-linking, subsequent cytotoxicity, and Treg depletion, potentially boosting tumor immune response. Pembrolizumab blocks the PD-1/PD-L1 interaction, restoring T cell-mediated antitumor activity. The combination is being studied for synergistic immunotherapeutic effects in patients with selected advanced solid tumors and lymphoma, particularly in those who have progressed on prior therapies[1][2][3][4][5].